All questions
Guidelines: Enhertu (fam-trastuzumab deruxtecan-nxki) in HR-positive HER2-low or HER2-ultralow breast cancer
1 question · 1 source
Guidelines questions that apply to every indication of Enhertu are on Enhertu (fam-trastuzumab deruxtecan-nxki), all indications: Guidelines.
Guidelines
What is the NCCN recommendation for Enhertu in HR-positive HER2-low breast cancer?
Note: NCCN Guidelines for Breast Cancer V.4.2026, accessed by the manufacturer June 12, 2026, as quoted on the Enhertu HCP site captured November 13, 2026. A later NCCN version may state the recommendation differently.